Index - P/E 105.04 EPS (ttm) 0.87 Insider Own 2.03% Shs Outstand 188.60M Perf Week 4.85%
Market Cap 17.37B Forward P/E 34.79 EPS next Y 2.63 Insider Trans -4.53% Shs Float 185.93M Perf Month 8.44%
Income 167.65M PEG 2.44 EPS next Q 0.32 Inst Own 98.66% Short Float 1.65% Perf Quarter -1.95%
Sales 2.42B P/S 7.18 EPS this Y 78.11% Inst Trans 2.05% Short Ratio 2.23 Perf Half Y 5.74%
Book/sh 26.25 P/B 3.49 EPS next Y 69.77% ROA 2.54% Short Interest 3.06M Perf Year -6.95%
Cash/sh 5.66 P/C 16.17 EPS next 5Y 43.00% ROE 3.51% 52W Range 76.02 - 100.38 Perf YTD -5.09%
Dividend Est. - P/FCF 277.56 EPS past 5Y - ROI 3.00% 52W High -8.84% Beta 0.31
Dividend TTM - Quick Ratio 1.57 Sales past 5Y 10.23% Gross Margin 76.15% 52W Low 20.38% ATR (14) 1.80
Dividend Ex-Date - Current Ratio 2.51 EPS Y/Y TTM 16.20% Oper. Margin 8.01% RSI (14) 66.62 Volatility 2.53% 1.86%
Employees 3401 Debt/Eq 0.23 Sales Y/Y TTM 18.16% Profit Margin 6.93% Recom 1.73 Target Price 109.75
Option/Short Yes / Yes LT Debt/Eq 0.13 EPS Q/Q 8269.23% Payout 0.00% Rel Volume 1.41 Prev Close 92.22
Sales Surprise 1.16% EPS Surprise -43.73% Sales Q/Q 25.23% Earnings Apr 24 AMC Avg Volume 1.37M Price 91.51
SMA20 5.07% SMA50 4.62% SMA200 2.86% Trades
Volume 1,941,479 Change -0.77%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-15-23 Initiated Wells Fargo
Overweight
$100
Oct-23-23 Upgrade Bernstein
Underperform → Mkt Perform
$82
Sep-28-23 Initiated Raymond James
Mkt Perform
Sep-18-23 Initiated UBS
Buy
$120
Jul-27-23 Initiated Scotiabank
Sector Perform
$95
Jul-05-23 Upgrade BMO Capital Markets
Market Perform → Outperform
$102
Jun-14-23 Resumed Credit Suisse
Outperform
$120
Mar-21-23 Initiated Bernstein
Underperform
$81
Feb-22-23 Downgrade Oppenheimer
Outperform → Perform
Feb-21-23 Initiated Citigroup
Neutral
$116
Jan-30-23 Initiated BMO Capital Markets
Market Perform
$107
Jan-18-23 Initiated Canaccord Genuity
Hold
$119
Oct-31-22 Upgrade Oppenheimer
Perform → Outperform
$92 → $110
Jul-13-22 Initiated Cantor Fitzgerald
Overweight
$110
Jun-13-22 Resumed Wedbush
Neutral
$146 → $70
Apr-25-22 Upgrade Morgan Stanley
Equal-Weight → Overweight
$96 → $113
Nov-22-21 Upgrade William Blair
Mkt Perform → Outperform
Oct-07-21 Resumed Jefferies
Buy
$100
Sep-09-21 Upgrade Stifel
Hold → Buy
$86 → $96
Jun-04-21 Resumed Robert W. Baird
Outperform
$101
Show Previous Ratings
Apr-12-24 07:00PM
Apr-10-24 08:00AM
Apr-01-24 07:01PM
Mar-17-24 08:50AM
Mar-16-24 05:06AM
08:30AM
Loading…
Mar-12-24 08:30AM
Mar-11-24 10:00AM
Mar-08-24 01:31AM
Mar-07-24 08:30AM
Mar-01-24 09:00AM
Feb-27-24 12:03AM
Feb-26-24 02:36PM
02:12PM
Feb-23-24 04:29PM
12:33PM
11:34AM
Loading…
11:34AM
07:21AM
(Thomson Reuters StreetEvents)
05:43AM
04:25AM
Feb-22-24 06:00PM
05:15PM
04:42PM
04:23PM
(Associated Press Finance)
04:03PM
Feb-19-24 09:15AM
Feb-15-24 10:00AM
Feb-13-24 01:10PM
Feb-08-24 04:10PM
08:00AM
Feb-07-24 05:21AM
08:30AM
Loading…
Feb-06-24 08:30AM
Jan-24-24 11:21AM
Jan-23-24 08:00AM
Jan-20-24 05:06AM
Jan-15-24 09:45AM
Jan-10-24 06:16PM
Jan-03-24 08:00AM
Dec-21-23 06:14AM
Dec-20-23 05:08PM
04:05PM
Dec-14-23 07:05PM
Dec-05-23 11:01AM
Dec-02-23 05:06AM
Dec-01-23 11:31AM
Nov-29-23 09:13PM
06:30AM
Nov-28-23 11:09AM
08:30AM
Nov-16-23 08:47AM
Nov-10-23 12:58AM
Nov-09-23 04:43PM
03:49AM
Nov-08-23 05:19AM
Nov-07-23 07:09PM
(Morningstar Research) +12.16%
05:07PM
(Investor's Business Daily)
02:24PM
Nov-06-23 07:20PM
Nov-04-23 05:06AM
Nov-03-23 01:23AM
Nov-02-23 05:02PM
12:17PM
08:44AM
07:15AM
Nov-01-23 06:30PM
05:55PM
05:02PM
(Associated Press Finance)
04:05PM
04:02PM
Oct-27-23 07:15AM
Oct-26-23 11:28AM
10:02AM
Oct-25-23 10:02AM
Oct-23-23 09:50AM
Oct-20-23 04:20PM
04:11PM
04:05PM
Oct-19-23 12:17PM
08:15AM
Oct-18-23 12:10PM
Oct-17-23 08:30AM
Sep-23-23 05:06AM
Sep-21-23 10:00AM
Sep-18-23 10:52AM
09:55AM
Sep-15-23 12:50PM
(Investor's Business Daily)
09:29AM
08:37AM
(Investor's Business Daily)
Sep-11-23 08:30AM
Sep-06-23 08:30AM
Sep-05-23 08:30AM
Sep-02-23 05:06AM
Sep-01-23 11:31AM
Aug-31-23 11:31AM
Aug-30-23 04:05PM
Aug-12-23 05:06AM
Aug-01-23 01:37PM
12:35PM
12:06PM
(Thomson Reuters StreetEvents)
Jul-31-23 07:30PM
05:35PM
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BIENAIME JEAN JACQUES Director Apr 12 '24 Option Exercise 63.10 20,000 1,262,000 494,994 Apr 15 04:21 PM BIENAIME JEAN JACQUES Director Apr 12 '24 Sale 91.26 20,000 1,825,200 474,994 Apr 15 04:21 PM BIENAIME JEAN JACQUES Director Apr 11 '24 Option Exercise 63.10 20,000 1,262,000 494,994 Apr 15 04:21 PM BIENAIME JEAN JACQUES Director Apr 11 '24 Sale 90.99 20,000 1,819,800 474,994 Apr 15 04:21 PM Burkhart Erin GVP, Chief Accounting Officer Apr 10 '24 Sale 90.00 2,286 205,740 16,156 Apr 12 03:07 PM Davis George Eric EVP, Chief Legal Officer Mar 28 '24 Sale 88.34 24,602 2,173,341 55,856 Apr 01 04:54 PM Slamon Dennis Director Mar 18 '24 Option Exercise 79.70 10,000 797,000 40,809 Mar 20 05:13 PM BIENAIME JEAN JACQUES Director Mar 06 '24 Sale 86.71 1,000 86,713 560,203 Mar 07 05:35 PM FUCHS HENRY J President, Worldwide R&D Mar 05 '24 Sale 85.18 35,341 3,010,396 212,117 Mar 07 06:54 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Mar 05 '24 Sale 87.07 4,000 348,280 94,047 Mar 07 05:32 PM BIENAIME JEAN JACQUES Director Mar 05 '24 Sale 85.51 1,000 85,510 561,203 Mar 07 05:35 PM BIENAIME JEAN JACQUES Director Feb 27 '24 Sale 90.35 1,000 90,350 562,203 Feb 29 05:05 PM BIENAIME JEAN JACQUES Director Feb 09 '24 Option Exercise 63.10 15,000 946,500 434,602 Feb 12 05:20 PM BIENAIME JEAN JACQUES Director Feb 09 '24 Sale 88.28 15,000 1,324,200 419,602 Feb 12 05:20 PM BIENAIME JEAN JACQUES Director Feb 08 '24 Option Exercise 63.10 15,000 946,500 434,602 Feb 12 05:20 PM BIENAIME JEAN JACQUES Director Feb 08 '24 Sale 89.77 15,000 1,346,550 419,602 Feb 12 05:20 PM BIENAIME JEAN JACQUES Director Jan 10 '24 Option Exercise 63.10 10,000 631,000 435,162 Jan 11 02:40 PM BIENAIME JEAN JACQUES Director Jan 10 '24 Sale 96.38 10,000 963,800 425,162 Jan 11 02:40 PM BIENAIME JEAN JACQUES Director Jan 09 '24 Option Exercise 63.10 10,000 631,000 435,162 Jan 11 02:40 PM BIENAIME JEAN JACQUES Director Jan 09 '24 Sale 98.19 10,000 981,900 425,162 Jan 11 02:40 PM BIENAIME JEAN JACQUES Director Dec 21 '23 Option Exercise 63.10 10,000 631,000 435,112 Dec 22 05:14 PM BIENAIME JEAN JACQUES Director Dec 21 '23 Sale 93.99 10,000 939,900 425,112 Dec 22 05:14 PM Davis George Eric EVP, Chief Legal Officer Dec 13 '23 Sale 95.30 13,764 1,311,709 55,710 Dec 14 06:18 PM Ajer Jeffrey Robert EVP, Chief Commercial Officer Aug 16 '23 Sale 90.00 5,000 450,000 60,804 Aug 17 03:57 PM FUCHS HENRY J President, Worldwide R&D Aug 10 '23 Sale 90.43 12,000 1,085,111 176,187 Aug 11 01:59 PM Guyer Charles Greg EVP, Chief Technical Officer Aug 09 '23 Sale 93.30 5,360 500,109 40,041 Aug 10 04:47 PM Davis George Eric EVP, Chief Legal Officer Aug 08 '23 Sale 89.42 11,000 983,662 69,474 Aug 09 07:08 PM BIENAIME JEAN JACQUES Chief Executive Officer Aug 08 '23 Sale 88.29 6,000 529,740 422,732 Aug 09 07:05 PM BIENAIME JEAN JACQUES Chief Executive Officer Aug 07 '23 Sale 88.10 4,000 352,400 428,732 Aug 09 07:05 PM BIENAIME JEAN JACQUES Chief Executive Officer May 12 '23 Option Exercise 67.81 46,500 3,153,165 472,713 May 16 05:22 PM MEIER RICHARD A Director May 12 '23 Option Exercise 67.81 8,500 576,385 117,494 May 17 06:14 PM HERON ELAINE J Director May 12 '23 Option Exercise 67.81 8,500 576,385 94,068 May 17 06:14 PM BIENAIME JEAN JACQUES Chief Executive Officer May 11 '23 Option Exercise 67.81 30,000 2,034,300 456,213 May 15 04:58 PM BIENAIME JEAN JACQUES Chief Executive Officer May 11 '23 Sale 94.67 30,000 2,840,226 426,213 May 15 04:58 PM BIENAIME JEAN JACQUES Chief Executive Officer May 10 '23 Option Exercise 67.81 30,000 2,034,300 456,213 May 11 05:04 PM BIENAIME JEAN JACQUES Chief Executive Officer May 10 '23 Sale 94.85 30,000 2,845,397 426,213 May 11 05:04 PM BIENAIME JEAN JACQUES Chief Executive Officer May 09 '23 Option Exercise 67.81 30,000 2,034,300 456,213 May 11 05:04 PM BIENAIME JEAN JACQUES Chief Executive Officer May 09 '23 Sale 94.93 30,000 2,847,973 426,213 May 11 05:04 PM
Index - P/E - EPS (ttm) -1.46 Insider Own 3.09% Shs Outstand 191.38M Perf Week 19.85%
Market Cap 288.28M Forward P/E - EPS next Y -0.71 Insider Trans -1.28% Shs Float 177.94M Perf Month 82.56%
Income -276.06M PEG - EPS next Q -0.19 Inst Own 65.28% Short Float 1.33% Perf Quarter 193.90%
Sales 90.12M P/S 3.20 EPS this Y 38.97% Inst Trans -4.28% Short Ratio 1.03 Perf Half Y 200.59%
Book/sh 0.68 P/B 2.29 EPS next Y 19.49% ROA -49.80% Short Interest 2.36M Perf Year 52.43%
Cash/sh 1.65 P/C 0.95 EPS next 5Y -7.30% ROE -110.95% 52W Range 0.41 - 1.75 Perf YTD 177.88%
Dividend Est. - P/FCF - EPS past 5Y - ROI -80.69% 52W High -10.29% Beta 0.73
Dividend TTM - Quick Ratio 6.14 Sales past 5Y -20.42% Gross Margin 62.53% 52W Low 280.51% ATR (14) 0.15
Dividend Ex-Date - Current Ratio 6.45 EPS Y/Y TTM 26.08% Oper. Margin -150.05% RSI (14) 75.52 Volatility 16.62% 11.31%
Employees 137 Debt/Eq 1.76 Sales Y/Y TTM -2.10% Profit Margin -306.31% Recom 3.00 Target Price 3.00
Option/Short Yes / Yes LT Debt/Eq 1.61 EPS Q/Q 30.53% Payout - Rel Volume 1.24 Prev Close 1.67
Sales Surprise 11.47% EPS Surprise -4.56% Sales Q/Q 8.45% Earnings Mar 04 AMC Avg Volume 2.30M Price 1.57
SMA20 45.84% SMA50 78.91% SMA200 143.10% Trades
Volume 2,846,826 Change -5.99%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Resumed JP Morgan
Underweight
Nov-09-23 Upgrade TD Cowen
Market Perform → Outperform
May-10-23 Upgrade Jefferies
Underperform → Hold
$1.50 → $1
Feb-24-23 Downgrade Jefferies
Hold → Underperform
$3.20 → $1.50
Aug-08-22 Downgrade JP Morgan
Neutral → Underweight
May-31-22 Resumed Jefferies
Hold
$12 → $4
Apr-18-22 Downgrade Goldman
Neutral → Sell
$3
Mar-15-22 Downgrade Mizuho
Buy → Neutral
$35 → $8
Mar-15-22 Downgrade Cowen
Outperform → Market Perform
Mar-14-22 Downgrade William Blair
Outperform → Mkt Perform
Mar-14-22 Downgrade Stifel
Buy → Hold
$24 → $5
Mar-14-22 Downgrade BTIG Research
Buy → Neutral
Mar-14-22 Downgrade BofA Securities
Neutral → Underperform
$18 → $6
Mar-09-22 Upgrade Oppenheimer
Perform → Outperform
$21
Nov-08-21 Upgrade The Benchmark Company
Hold → Buy
$20
Sep-10-21 Initiated BofA Securities
Neutral
$18
Jun-28-21 Upgrade Stifel
Hold → Buy
$22 → $24
May-18-21 Resumed Goldman
Neutral
$24
Feb-22-21 Downgrade The Benchmark Company
Buy → Hold
Jan-06-21 Initiated Stifel
Hold
$18
Show Previous Ratings
Apr-03-24 11:30AM
Mar-25-24 10:00AM
Mar-22-24 02:00PM
Mar-06-24 12:33PM
Mar-05-24 10:07AM
09:13AM
Loading…
09:13AM
09:00AM
07:19AM
(Thomson Reuters StreetEvents)
Mar-04-24 05:30PM
04:51PM
04:42PM
(Associated Press Finance)
04:15PM
08:30AM
Feb-27-24 06:00PM
Feb-26-24 06:00PM
10:00AM
Loading…
Feb-20-24 10:00AM
Jan-03-24 06:00PM
Dec-11-23 06:00PM
Dec-07-23 11:31AM
Nov-09-23 08:39AM
Nov-08-23 11:47AM
Nov-07-23 05:28PM
(Associated Press Finance)
04:15PM
Oct-31-23 06:00PM
Oct-26-23 10:02AM
Oct-23-23 10:08AM
Oct-13-23 08:30AM
Oct-02-23 09:00AM
Sep-27-23 09:00AM
Sep-14-23 07:54AM
09:00AM
Loading…
Sep-13-23 09:00AM
Sep-07-23 11:31AM
Sep-06-23 06:00PM
Aug-17-23 07:02PM
Aug-09-23 09:25AM
Aug-08-23 05:30PM
04:23PM
04:15PM
11:08AM
(American City Business Journals)
Aug-07-23 10:23AM
06:30AM
Aug-01-23 06:00PM
Jul-24-23 03:48AM
Jul-16-23 08:49AM
Jun-12-23 06:00PM
Jun-08-23 12:55PM
11:31AM
May-10-23 11:28AM
09:16AM
May-09-23 06:45PM
05:41PM
04:15PM
May-08-23 09:29AM
May-04-23 10:00AM
May-02-23 10:01AM
Apr-27-23 08:30AM
Apr-19-23 08:38AM
Apr-17-23 05:00PM
Apr-16-23 06:30AM
Apr-13-23 10:59AM
Apr-11-23 08:57AM
Apr-10-23 10:07AM
Apr-02-23 08:27AM
Mar-30-23 11:30AM
Mar-29-23 05:44PM
Mar-24-23 12:00PM
Mar-22-23 09:35AM
Mar-14-23 03:43AM
Feb-28-23 05:15PM
Feb-24-23 10:23AM
07:29AM
Feb-23-23 06:20PM
05:24PM
04:30PM
Jan-09-23 09:04AM
Jan-04-23 09:00AM
Dec-12-22 10:05AM
Dec-05-22 08:00AM
Nov-10-22 09:05AM
07:58AM
Nov-09-22 09:00AM
Nov-04-22 12:35PM
Nov-03-22 06:35PM
Oct-28-22 10:00AM
Oct-27-22 10:02AM
Oct-25-22 06:00PM
Oct-24-22 07:55AM
Oct-11-22 05:13PM
(American City Business Journals)
Oct-07-22 03:42PM
(American City Business Journals)
11:21AM
Sep-07-22 01:15AM
Aug-21-22 09:57AM
Aug-16-22 08:30AM
Aug-05-22 12:11PM
Aug-04-22 06:15PM
04:15PM
Jul-26-22 06:00PM
Jul-14-22 06:01AM
Jul-01-22 06:30AM
May-27-22 08:00AM
(American City Business Journals)
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROBIN HOWARD W President & CEO Feb 20 '24 Sale 0.68 20,033 13,622 879,889 Feb 22 08:16 PM Zalevsky Jonathan Chief R&D Officer Feb 20 '24 Sale 0.68 9,014 6,130 265,025 Feb 22 08:19 PM Wilson Mark Andrew Chief Legal Officer Feb 20 '24 Sale 0.68 7,606 5,172 236,674 Feb 22 08:17 PM ROBIN HOWARD W President & CEO Nov 17 '23 Sale 0.49 19,877 9,740 899,922 Nov 20 08:58 PM Zalevsky Jonathan Chief R&D Officer Nov 17 '23 Sale 0.49 9,646 4,727 274,039 Nov 20 09:02 PM Wilson Mark Andrew Chief Legal Officer Nov 17 '23 Sale 0.49 7,179 3,518 243,780 Nov 20 09:00 PM Curet Myriam Director Sep 18 '23 Sale 0.69 4,359 3,008 27,418 Sep 20 08:09 PM Ajer Jeffrey Robert Director Sep 18 '23 Sale 0.69 4,359 3,008 34,153 Sep 20 08:06 PM ROBIN HOWARD W President & CEO Aug 16 '23 Sale 0.78 19,998 15,598 919,799 Aug 17 08:06 PM Zalevsky Jonathan Chief R&D Officer Aug 16 '23 Sale 0.78 9,703 7,568 283,685 Aug 17 08:08 PM Wilson Mark Andrew Chief Legal Officer Aug 16 '23 Sale 0.78 7,221 5,632 250,959 Aug 17 08:07 PM WHITFIELD ROY A Director Jun 14 '23 Sale 0.57 30,000 17,100 216,250 Jun 15 06:26 PM ROBIN HOWARD W President & CEO May 16 '23 Sale 0.72 20,361 14,660 939,797 May 17 08:27 PM Zalevsky Jonathan Chief R&D Officer May 16 '23 Sale 0.72 9,791 7,050 293,388 May 17 08:29 PM Wilson Mark Andrew Chief Legal Officer May 16 '23 Sale 0.72 7,543 5,431 257,680 May 17 08:28 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
